4,006 Shares in Kodiak Sciences Inc. (NASDAQ:KOD) Acquired by US Bancorp DE

US Bancorp DE acquired a new position in shares of Kodiak Sciences Inc. (NASDAQ:KODFree Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 4,006 shares of the company’s stock, valued at approximately $40,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. JPMorgan Chase & Co. lifted its holdings in Kodiak Sciences by 220.9% in the 3rd quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company’s stock valued at $117,000 after purchasing an additional 30,735 shares in the last quarter. SG Americas Securities LLC grew its position in shares of Kodiak Sciences by 61.4% during the fourth quarter. SG Americas Securities LLC now owns 20,684 shares of the company’s stock worth $206,000 after buying an additional 7,871 shares in the last quarter. Barclays PLC grew its position in shares of Kodiak Sciences by 65.5% during the third quarter. Barclays PLC now owns 79,658 shares of the company’s stock worth $208,000 after buying an additional 31,527 shares in the last quarter. FMR LLC lifted its stake in Kodiak Sciences by 26.4% during the third quarter. FMR LLC now owns 200,971 shares of the company’s stock worth $525,000 after purchasing an additional 41,987 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in Kodiak Sciences by 5.3% during the fourth quarter. Bank of New York Mellon Corp now owns 98,102 shares of the company’s stock worth $976,000 after purchasing an additional 4,927 shares during the last quarter. Institutional investors and hedge funds own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Jefferies Financial Group raised Kodiak Sciences from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a report on Monday, December 9th.

View Our Latest Analysis on KOD

Kodiak Sciences Stock Performance

KOD stock opened at $3.24 on Wednesday. Kodiak Sciences Inc. has a 1 year low of $2.19 and a 1 year high of $11.60. The firm has a market cap of $170.50 million, a P/E ratio of -0.89 and a beta of 2.26. The stock has a 50-day simple moving average of $5.66 and a 200-day simple moving average of $5.40.

About Kodiak Sciences

(Free Report)

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.

Read More

Want to see what other hedge funds are holding KOD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kodiak Sciences Inc. (NASDAQ:KODFree Report).

Institutional Ownership by Quarter for Kodiak Sciences (NASDAQ:KOD)

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.